BioRem Inc.
BioRem Inc. Fundamental Analysis
BioRem Inc. (BIRMF) shows moderate financial fundamentals with a PE ratio of 18.40, profit margin of 6.08%, and ROE of 18.99%. The company generates $0.0B in annual revenue with strong year-over-year growth of 48.69%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 70.7/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze BIRMF's fundamental strength across five key dimensions:
Efficiency Score
WeakBIRMF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentBIRMF trades at attractive valuation levels.
Growth Score
ExcellentBIRMF delivers strong and consistent growth momentum.
Financial Health Score
ExcellentBIRMF maintains a strong and stable balance sheet.
Profitability Score
ModerateBIRMF maintains healthy but balanced margins.
Key Financial Metrics
Is BIRMF Expensive or Cheap?
P/E Ratio
BIRMF trades at 18.40 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, BIRMF's PEG of -0.38 indicates potential undervaluation.
Price to Book
The market values BioRem Inc. at 3.18 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 12.37 times EBITDA. This signals the market has high growth expectations.
How Well Does BIRMF Make Money?
Net Profit Margin
For every $100 in sales, BioRem Inc. keeps $6.08 as profit after all expenses.
Operating Margin
Core operations generate 8.78 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.99 in profit for every $100 of shareholder equity.
ROA
BioRem Inc. generates $7.60 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioRem Inc. generates limited operating cash flow of $2.57M, signaling weaker underlying cash strength.
Free Cash Flow
BioRem Inc. produces free cash flow of $2.23M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.14 in free cash annually.
FCF Yield
BIRMF converts 5.73% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
18.40
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.38
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.18
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.12
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.89
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.19
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.21
vs 25 benchmark
How BIRMF Stacks Against Its Sector Peers
| Metric | BIRMF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 18.40 | 25.96 | Better (Cheaper) |
| ROE | 18.99% | 1263.00% | Weak |
| Net Margin | 6.08% | -41827.00% (disorted) | Weak |
| Debt/Equity | 0.25 | 0.79 | Strong (Low Leverage) |
| Current Ratio | 1.89 | 10.05 | Neutral |
| ROA | 7.60% | -1497918.00% (disorted) | Weak |
BIRMF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioRem Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
344.41%
Industry Style: Cyclical, Value, Infrastructure
High GrowthEPS CAGR
673.13%
Industry Style: Cyclical, Value, Infrastructure
High GrowthFCF CAGR
257.55%
Industry Style: Cyclical, Value, Infrastructure
High Growth